The efficacy of platelet rich plasma in the treatment of erectile dysfunction: a systematic review and meta-analysis of randomized controlled trials.

IF 2.7 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Aging Male Pub Date : 2024-12-01 Epub Date: 2024-06-04 DOI:10.1080/13685538.2024.2358944

Qiancheng Mao, Yingying Yang, Yang Liu, Hongquan Liu, Gonglin Tang, Xiaofeng Wang, Yuanshan Cui, Jitao Wu

{"title":"The efficacy of platelet rich plasma in the treatment of erectile dysfunction: a systematic review and meta-analysis of randomized controlled trials.","authors":"Qiancheng Mao, Yingying Yang, Yang Liu, Hongquan Liu, Gonglin Tang, Xiaofeng Wang, Yuanshan Cui, Jitao Wu","doi":"10.1080/13685538.2024.2358944","DOIUrl":null,"url":null,"abstract":"Background: Erectile dysfunction (ED) is a common issue among males, and the use of platelet-rich plasma (PRP) therapy for treating ED has gained increasing attention, but there is still no conclusive evidence regarding its efficacy.Aim: To evaluate the efficacy of PRP therapy for ED.Methods: We systematically searched PubMed, Embase, Cochrane Library, and Web of Science databases up to November 2023 to identify randomized controlled trials (RCTs) on PRP therapy for ED. We used Review Manager version 5.4 for data analysis and management.Result: After applying inclusion and exclusion criteria for screening, a total of 4 studies involving 413 patients were finally included in our meta-analysis. According to our analysis, the PRP group showed significant advantages over the placebo group in terms of MCID at the first month (p = 0.03) and sixth months (p = 0.008), while there was no significant difference between the two groups at the third month (p = 0.19). Additionally, in terms of IIEF, PRP showed significantly better efficacy than placebo at the first, third, and sixth months (p < 0.00001).Conclusions: PRP shows more effectiveness in treating ED compared to placebo, offering hope as a potential alternative treatment for ED.","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging Male","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13685538.2024.2358944","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Erectile dysfunction (ED) is a common issue among males, and the use of platelet-rich plasma (PRP) therapy for treating ED has gained increasing attention, but there is still no conclusive evidence regarding its efficacy.

Aim: To evaluate the efficacy of PRP therapy for ED.

Methods: We systematically searched PubMed, Embase, Cochrane Library, and Web of Science databases up to November 2023 to identify randomized controlled trials (RCTs) on PRP therapy for ED. We used Review Manager version 5.4 for data analysis and management.

Result: After applying inclusion and exclusion criteria for screening, a total of 4 studies involving 413 patients were finally included in our meta-analysis. According to our analysis, the PRP group showed significant advantages over the placebo group in terms of MCID at the first month (p = 0.03) and sixth months (p = 0.008), while there was no significant difference between the two groups at the third month (p = 0.19). Additionally, in terms of IIEF, PRP showed significantly better efficacy than placebo at the first, third, and sixth months (p < 0.00001).

Conclusions: PRP shows more effectiveness in treating ED compared to placebo, offering hope as a potential alternative treatment for ED.

查看原文本刊更多论文

富血小板血浆治疗勃起功能障碍的疗效：随机对照试验的系统回顾和荟萃分析。

背景：勃起功能障碍（ED）是男性的常见问题，使用富血小板血浆（PRP）疗法治疗ED已受到越来越多的关注，但关于其疗效仍没有确凿的证据：我们系统地检索了截至 2023 年 11 月的 PubMed、Embase、Cochrane Library 和 Web of Science 数据库，以确定 PRP 治疗 ED 的随机对照试验 (RCT)。我们使用Review Manager 5.4版本进行数据分析和管理：结果：在采用纳入和排除标准进行筛选后，我们的荟萃分析最终纳入了共 4 项研究，涉及 413 名患者。根据我们的分析，在第一个月（p = 0.03）和第六个月（p = 0.008）的 MCID 方面，PRP 组比安慰剂组有显著优势，而在第三个月（p = 0.19），两组之间没有显著差异。此外，在 IIEF 方面，PRP 在第一个月、第三个月和第六个月的疗效明显优于安慰剂（p 结论：PRP 对治疗男性性功能障碍更有效：与安慰剂相比，PRP 在治疗 ED 方面更有效，有望成为 ED 的一种潜在替代疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Aging Male 医学-泌尿学与肾脏学

CiteScore

6.40

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Aging Male , the official journal of the International Society for the Study of the Aging Male, is a multidisciplinary publication covering all aspects of male health throughout the aging process. The Journal is a well-recognized and respected resource for anyone interested in keeping up to date with developments in this field. It is published quarterly in one volume per year. The Journal publishes original peer-reviewed research papers as well as review papers and other appropriate educational material that provide researchers with an integrated perspective on this new, emerging specialty. Areas of interest include, but are not limited to: Diagnosis and treatment of late-onset hypogonadism Metabolic syndrome and related conditions Treatment of erectile dysfunction and related disorders Prostate cancer and benign prostate hyperplasia.